Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HMBD-002 |
| Synonyms | |
| Therapy Description |
HMBD-002 is an antibody that targets VISTA (VSIR; PD1H), potentially resulting in relief of immunosuppression and reduced tumor growth (J Clin Oncol 39:15_suppl, e14569). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HMBD-002 | HMBD002|HMBD 002 | VSIR Antibody 6 | HMBD-002 is an antibody that targets VISTA (VSIR; PD1H), potentially resulting in relief of immunosuppression and reduced tumor growth (J Clin Oncol 39:15_suppl, e14569). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05082610 | Phase I | HMBD-002 HMBD-002 + Pembrolizumab | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | Completed | USA | 0 |